Literature DB >> 9104736

Systemic lupus erythematosus with acanthosis nigricans, hyperpigmentation, and insulin receptor antibody.

J S Baird1, J L Johnson, D Elliott-Mills, L M Opas.   

Abstract

Acanthosis nigricans, insulin receptor antibody, and systemic lupus erythematosus are associated in the potentially lethal syndrome of type B insulin resistance. Hyperpigmentation has been reported rarely, while glucose intolerance is common in these patients. We report an adolescent girl with acanthosis nigricans, hyperpigmentation, insulin receptor antibody, and systemic lupus erythematosus without glucose intolerance. Insulin resistance may be mild or transient in some patients with type B insulin resistance. Resolution of skin lesions was noted during therapy of SLE, and was associated with disappearance of insulin receptor antibody.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9104736     DOI: 10.1177/096120339700600311

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

Review 1.  [Lupus erythematosus. Wide range of symptoms through clinical variation, associated diseases and imitators].

Authors:  E Aberer
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

2.  Acral Acanthosis Nigricans in a Case of Scleroderma.

Authors:  Mahendra M Kura; Swapnil A Sanghavi
Journal:  Indian J Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.494

3.  Clinical evaluation of insulin resistance and beta-cell function by the homeostasis model assessment in patients with systemic lupus erythematosus.

Authors:  Tim K Tso; Hui-Yu Huang; Chen-Kang Chang; Ying-Ju Liao; Wen-Nan Huang
Journal:  Clin Rheumatol       Date:  2004-05-18       Impact factor: 2.980

4.  A case of generalized acanthosis nigricans with positive lupus erythematosus-related autoantibodies and antimicrosomal antibody: autoimmune acanthosis nigricans?

Authors:  Y Kondo; N Umegaki; M Terao; H Murota; T Kimura; I Katayama
Journal:  Case Rep Dermatol       Date:  2012-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.